Development of medical countermeasures for biodefense and emerging infectious diseases, base, option 1 and option 2 award, 09/16/2013 - 09/15/2017

Ended Definitive Contract Awarded Last action

Contract number
HHSN272201300017C
Awardee
Awarding agency
Obligated
$47,755,723

Award facts

Contract value 100% obligated
$47,755,722.77 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 28 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Durham, NC 27703, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00026 · Due to changes in the overhead a cost overrun transpired. To close out this contract funds are being added to pay the obligation. Total amount of contract is… $440,828
Change Order P00025 $1,383,666
Other Administrative Action P00024 $0
Supplemental Agreement for work within scope P00023 · Biocryst; development of therapeutic medical countermeasures for biodefense and emerging infectious diseases $2,896,627
Change Order 22 $3,557,707
Other Administrative Action 21 $0
Other Administrative Action 20 $0
Funding Only Action 19 $4,126,697
Change Order 18 $5,475,146
Other Administrative Action 17 $0
Other Administrative Action 16 $0
Other Administrative Action 15 $0
Funding Only Action 14 · 1300017C biocryst; development of therapeutic medical countermeasures for biodefense and emerging infectious diseases; option 4 E5 equitable adjustment; biod… $3,529,515
Funding Only Action 13 $0
Change Order 12 $1,324,757
Other Administrative Action 11 $0
Funding Only Action 10 $2,718,329
Funding Only Action 9 $2,390,324
Exercise an Option 8 $6,986,545
Other Administrative Action 7 -$2,957,901
Funding Only Action 6 $2,406,848
Exercise an Option 5 $4,088,185
Other Administrative Action 4 $0
Exercise an Option 3 $1,886,304
Change Order 2 $0
Exercise an Option 1 $2,506,042
Original award $4,996,104
Show all 27

About this award

Written by GovTribe AI ·

This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in small molecule drugs for rare diseases. The $47,755,722.77 cost-plus-fixed-fee contract is for the development of medical countermeasures for biodefense and emerging infectious diseases. The contract has a base period from September 16, 2013, to September 15, 2017, with two option periods extending the performance through September 30, 2022. This contract is not associated with any set-aside designation. Biocryst Pharmaceuticals holds several federal contract vehicles, including a $1.25 million Federal Supply Schedule contract and two Blanket Purchase Agreements with the Department of Veterans Affairs, which facilitate the procurement of Biocryst's pharmaceutical products, such as ORLADEYO for hereditary angioedema and RAPIVAB for influenza treatment, by government agencies.

Quick answers

Who was awarded contract HHSN272201300017C?

HHSN272201300017C was awarded to Biocryst Pharmaceuticals Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 16, 2013.

How much is contract HHSN272201300017C worth?

The government has obligated $47,755,723 on HHSN272201300017C.

Was contract HHSN272201300017C competed?

The extent of competition for HHSN272201300017C was full and open competition. The government received 28 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login